Atlassian uses cookies to improve your browsing experience, perform analytics and research, and conduct advertising. Accept all cookies to indicate that you agree to our use of cookies on your device. Atlassian cookies and tracking notice, (opens new window)
/
Developing Predictive Models to Facilitate Interpretation of Toxicology Study Results

    Developing Predictive Models to Facilitate Interpretation of Toxicology Study Results

    Oct 01, 2025

    Project Scope 

    A computational pipeline to build models to predict target organs of toxicity from SEND datasets has been developed and published on GitHub under PHUSE. Project team members will evaluate the feasibility and performance of this pipeline when run on data from within their organisations. The pipeline will be updated to improve compatibility with different database systems, and efforts will be made to improve its performance across disparate data sources. Additional study interpretations – e.g. adversity of findings, NOAEL determination, clinical translatability, structure activity relationship – will be explored for development of predictive models. Successful modeling approaches will be published in peer-reviewed scientific journal articles.

    Problem Statement 

    Expert toxicologists spend hours interpreting the results of multiple studies to support the safety of new drug products. SEND data has enabled the construction of large databases of toxicology study results for building predictive models. These models can be trained using expert interpretations of old study data to make predictions that will streamline the interpretation of future studies.

    Problem Impact 

    Many hours are spent by both industry toxicologists and regulatory authority reviewers attempting to properly integrate and interpret the results of toxicology studies conducted to support drug safety. SEND data can be used to train models to use prior interpretations to predict likely interpretations of current studies. This approach will decrease time spent reviewing study results and increase study interpretation across toxicologists because the models will be trained on their interpretive conclusions. The models may also provide valuable insight into which toxicology study endpoints are most relevant for prediction of specific interpretations, e.g. hepatotoxicity, nephrotoxicity.

    Project LeadsEmail 
    Kevin Snyder, FDA

    Kevin.Snyder@fda.hhs.gov

    Lennart Anger, Genentech

    Anger.lennart@gene.com
    Alex Pearce, PHUSE Project AssistantAlexandra@phuse.global

    CURRENT STATUS (Updated Quarterly) 

    • Continuing to host talks from project members highlighting the use cases for predictive modelling of toxicology data in their organisations​​

    • Continue presentation series​​​

    Objectives & DeliverablesTimelines
    Evaluate the feasibility and performance of target organ prediction models developed by the FDA on data from other project members’ organisationsQ4 2024
    Identify and prioritise a list of modeling endpoints – i.e. study interpretations – which would be most useful for additional predictive modeling approaches. Q4 2024
    Iteratively improve upon the FDA modeling approach and develop, implement and test additional modeling approachesQ3 2025
    Draft a manuscript describing successful modeling approachesQ3 2025
    , multiple selections available,
    Welcome to the PHUSE Advance Hub
    Teams
    , (opens new window)

    WORKING GROUPS
    Results will update as you type.
    • Working Groups
      • Data Transparency
      • Data Visualisation & Open Source Technology
      • Emerging Trends & Innovation
      • Nonclinical Topics
        • Conformance with the tumor.xpt Specification
        • Developing Predictive Models to Facilitate Interpretation of Toxicology Study Results
        • Nonclinical Study Data Reviewer's Guide
        • SEND Coding Bootcamp
        • SEND Industry Feedback Survey
        • Supporting the Use of SEND for the Implementation of Virtual Control Groups
      • Optimizing the Use of Data Standards
      • pharmaverse
      • Real World Evidence
      • Risk Based Quality Management
      • Safety Analytics
    • Hot Topics
    • Useful Information
    • Deliverables
    • Working Groups Events
    • Working Groups Report – Q3 2025
    • Working Groups Archive
    • Working Groups Events Archive
      You‘re viewing this with anonymous access, so some content might be blocked.
      {"serverDuration": 10, "requestCorrelationId": "611b76c099b343809005d646cc49ee17"}